The new treatment for condyloma acuminatum – ALA-photodynamic therapy Condyloma acuminatum is an epidermal neoplastic growth in the genital, perineal and anal areas caused by human papillomavirus (HPV) infection, and is the most common sexually transmitted disease worldwide. In the past, ordinary laser treatment was generally used, but the patient suffered a lot of pain during treatment, slow recovery after treatment, easy to produce scarring and lead to urethral stricture. Aminoketovaleric acid (ALA) is a precursor to the synthesis process of ferrous hemoglobin in the human body. Under normal conditions, ALA is present in small intracellular amounts and does not itself produce photosensitivity. After exogenous ALA enters the body, it is converted into strong photosensitizers such as protoporphyrin IX in cells, which generates reactive oxygen species and free radicals after illumination with specific wavelengths and energies. HPV-infected cells are actively proliferating, and the accumulated concentration of protoporphyrin IX is higher than that of surrounding normal tissues after drug administration, which can kill wart tissues with specific wavelengths and energies of light irradiation, while affecting surrounding normal tissues less. The wart clearance rate of ALA – photodynamic therapy for warts is 98.42%, but the recurrence rate is significantly lower than that of freezing as well as laser treatment. In terms of safety, the incidence of adverse reactions of ALA-photodynamic therapy was significantly lower than that of cryotherapy, indicating that ALA-photodynamic therapy is safe and effective in treating condyloma acuminata, with a high cure rate and a low recurrence rate, which is worth promoting in clinical practice. The company’s main goal is to provide a comprehensive range of products and services to the marketplace, including the following